Usona Wants to Import Magic Mushrooms and Mescaline Legally
Published Date: 3/30/2026
Notice
Summary
Usona Institute wants to become an official importer of some powerful controlled substances like mescaline and psilocybin. People who make or use these drugs can share their thoughts or ask for a hearing by April 29, 2026. This move could impact research and medical use, with no direct cost changes announced yet.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
Usona applies to import five Schedule I drugs
On March 2, 2026, Usona Institute applied to be registered as an importer of five Schedule I controlled substances: mescaline (code 7381), 5‑Methoxy‑N‑N‑dimethyltryptamine (7431), dimethyltryptamine (7435), psilocybin (7437), and psilocyn (7438). The company says it plans to import these materials for research and analytical purposes only.
Imports barred for clinical use or commercial sale
The application specifies that the imported materials will not be used for clinical trials or human consumption. Approval will not authorize import of Food and Drug Administration‑approved or non‑approved finished dosage forms for commercial sale.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20535, Arenbii Pharmacy LLC; Decision and Order
Arenbii Pharmacy in Texas lost its DEA license because it kept filling risky drug prescriptions without fixing obvious problems. This means they can’t legally handle certain controlled medicines anymore, protecting public safety. The decision is final, and Arenbii didn’t ask for a hearing, so the revocation starts now with no chance to appeal.
2026-20553, Decision and Order: Medpharm Research, LLC
Medpharm Research, LLC wanted to get official permission to make marijuana in bulk, but the DEA said no. The DEA found that Medpharm’s related companies were handling marijuana without permission and even selling it for recreational use, which breaks the rules. So, Medpharm’s application was denied, and they can’t legally manufacture marijuana in bulk now.
Previous / Next Documents
Previous: 2026-06050, Taking and Importing Marine Mammals; Taking Marine Mammals Incidental to the Washington State Parks and Recreation Commission's Marine Facilities Replacement Program in North Puget Sound, Washington
The Washington State Parks want permission to accidentally disturb marine mammals while fixing up marine facilities in North Puget Sound for the next 5 years. The National Oceanic and Atmospheric Administration (NOAA) is asking the public to share their thoughts by April 29, 2026. This project affects local sea animals but helps improve park facilities without a direct cost impact mentioned.
Next: 2026-06052, Bulk Manufacturer of Controlled Substances Application: Chemtos, LLC
Chemtos, LLC wants to become a big-time maker of certain controlled substances, including some strong and tightly regulated drugs. People and companies involved with these substances can share their thoughts or ask for a hearing by May 29, 2026. This move could shake up the supply chain and means Chemtos is stepping into a serious role with important deadlines and rules to follow.